Senti Biosciences, Inc. (SNTI)

Senti Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-58.32	-52.79	-71.06	-58.21	-55.32
Depreciation & Amortization	3.72	5.85	5.43	3.92	3.01
Stock-Based Compensation	4	1.76	9.67	16.39	2.3
Other Adjustments	-	-0.26	-1.1	-10.9	14.76
Change in Receivables	-2.54	-0.73	-0.93	-0.13	-0.4
Changes in Accounts Payable	0.67	0.8	-0.29	0.19	-0.62
Changes in Accrued Expenses	1.28	-0.67	0.72	2.06	2.57
Changes in Unearned Revenue	-	-	-0.8	-1.03	1.83
Changes in Other Operating Activities	-2.04	4.64	5.97	12.83	-2.78
Operating Cash Flow	-48.49	-41.4	-52.4	-34.9	-34.64
Capital Expenditures	-	-0.03	-12.04	-41.37	-5.54
Sale of Property, Plant & Equipment	-	0.06	0.11	-	-
Purchases of Investments	-	-	-17.99	-40.59	-
Proceeds from Sale of Investments	-	-	60	-	-
Investing Cash Flow	-0.14	0.03	30.08	-81.96	-5.54
Long-Term Debt Issued	-	-	-	5.18	-
Net Long-Term Debt Issued (Repaid)	-	-	-	5.18	-
Issuance of Common Stock	-	49.06	0.89	113.38	1.48
Net Common Stock Issued (Repurchased)	-	49.06	0.89	113.38	1.48
Issuance of Preferred Stock	-	-	-	-	66.95
Net Preferred Stock Issued (Repurchased)	-	-	-	-	66.95
Other Financing Activities	7.42	4.67	-0.11	-	-
Financing Cash Flow	54.33	53.73	0.78	118.55	68.44
Net Cash Flow	5.7	12.37	-21.54	1.7	28.26
Beginning Cash & Cash Equivalents	19.41	39.45	60.99	59.29	31.03
Ending Cash & Cash Equivalents	25.11	51.82	39.45	60.99	59.29
Free Cash Flow	-48.49	-41.42	-64.43	-76.27	-40.18
FCF Margin	-	-	-2515.93%	-1779.51%	-1455.20%
Free Cash Flow Per Share	-4.28	-9.01	-14.52	-29.21	-137.96
Levered Free Cash Flow	-54.68	-42.2	-72.07	-76.45	-56.84
Unlevered Free Cash Flow	-60.94	-50.44	-93.74	-85.5	-41.97

Updated Aug 7, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q